FDA Approves Belzutifan/Pembrolizumab for Adjuvant Renal Cell Carcinoma

The US Food and Drug Administration (FDA) has announced the approval of belzutifan (Welireg) in combination with pembrolizumab (Keytruda) for the adjuvant treatment of adult patients with clear cell renal cell carcinoma (ccRCC).

This combination therapy, which may also utilize pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), is indicated for patients at intermediate-high or high risk of recurrence following a nephrectomy, or following nephrectomy and the resection of metastatic lesions.

Clinical Evidence: The LITESPARK-022 trial

The approval was supported by data from LITESPARK-022 (NCT05239728), a multicenter, randomized, double-blind trial that enrolled 1,841 patients. Participants had previously undergone a nephrectomy for ccRCC and were identified as having a high risk of recurrence or resected metastases with no current evidence of disease.

Patients were randomized 1:1 to receive either the belzutifan-pembrolizumab combination or a placebo-pembrolizumab regimen. Treatment continued until disease recurrence, unacceptable toxicity, or for a maximum duration of 54 weeks for belzutifan and 12 months for pembrolizumab.

The primary efficacy outcome was investigator-assessed disease-free survival (DFS). At a prespecified interim analysis, the belzutifan-pembrolizumab arm showed a statistically significant improvement in DFS compared to the placebo-pembrolizumab arm. There were 186 events reported in the combination group versus 246 in the control group, resulting in a hazard ratio of 0.72 (95% CI: 0.59, 0.87; p-value 0.0003). While DFS showed clear benefit, median DFS was not reached in either arm, and overall survival data remained immature at the time of the analysis.

Nursing considerations: Safety and monitoring

For oncology nurses, managing the unique safety profiles of this combination therapy is paramount. The prescribing information for belzutifan includes a boxed warning for embryo-fetal toxicity. Additionally, nurses should monitor patients closely for anemia and hypoxia, which are listed as key warnings and precautions.

Pembrolizumab also carries significant warnings, including immune-mediated adverse reactions, infusion-related reactions, and potential complications if a patient undergoes an allogeneic hematopoietic stem cell transplantation. Nurses should educate patients on recognizing early signs of these reactions and emphasize the importance of reporting any new or worsening symptoms.

Dosage and administration

The recommended dosing schedule for this combination is as follows:

• Belzutifan: 120 mg administered orally once daily for up to 54 weeks or until recurrence/toxicity.
• Pembrolizumab: 200 mg intravenously every three weeks or 400 mg every six weeks for up to 12 months.
• Subcutaneous Option: If using pembrolizumab and berahyaluronidase alfa-pmph, the dose is 395 mg/4,800 units every three weeks or 790 mg/9,600 units every six weeks for up to 12 months.

Regulatory context

The FDA granted this application priority review and conducted the evaluation under Project Orbis. This international framework allowed for the concurrent submission and review of the drug among global partners, including the Australian Therapeutic Goods Administration and Health Canada.

Healthcare professionals are encouraged to report any serious adverse events through the FDA’s MedWatch Reporting System. This approval marks a significant expansion in the adjuvant treatment landscape for high-risk renal cell carcinoma, offering a new standard for patients following surgical intervention.

Reference

1. FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. FDA. June 12, 2026. Accessed June 12, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma